Lantheus Acquires Global Rights to Life Molecular Imaging's Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers

"While new PSMA-targeted diagnostics and therapeutics are transforming prostate cancer care, there are many patients for whom PSMA-targeted therapy may not be appropriate," said Brian Markison, Lantheus CEO. "Targeting GRPR with 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 creates a potential new option to expand access to radiotheranostics for more prostate cancer patients. This expands our therapeutic offerings and opens avenues for commercial synergies." Wolf, Greenfield & Sacks, P.C. acted as legal advisor to Lanth ...